TRIANA Biomedicines Enters Collaboration with Pfizer for Molecular Glue Discovery

TRIANA Biomedicines, Inc. has announced a strategic collaboration with Pfizer aimed at discovering novel molecular glue degraders for multiple disease targets, with a focus on oncology. Under this agreement, TRIANA will receive an upfront payment of $49 million and stands to gain milestone payments exceeding $1.5 billion, alongside tiered royalties.

This partnership leverages TRIANA's advanced molecular glue platform to tackle hard-to-address disease targets. TRIANA will lead the discovery process, while Pfizer holds an exclusive option to proceed with preclinical and clinical developments. This collaboration emphasizes Pfizer's commitment to innovative cancer treatments and highlights TRIANA's role in pioneering groundbreaking therapeutic strategies.